Equities

iSpecimen Inc

ISPC:NAQ

iSpecimen Inc

Actions
Health CareHealth Care Providers
  • Price (USD)4.30
  • Today's Change-0.18 / -4.02%
  • Shares traded204.45k
  • 1 Year change-60.91%
  • Beta1.6026
Data delayed at least 15 minutes, as of Nov 13 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

iSpecimen Inc. is a technology-driven company. The Company's iSpecimen Marketplace platform is designed to transform the biospecimen procurement process to accelerate medical discovery. The Company's technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. Its iSpecimen Marketplace platform has compiled de-identified healthcare data provided by its healthcare supply partners. The platform is built upon a robust healthcare data set comprised of information about available specimens and research subjects. The Company’s platform helps with administrative and reporting functions for researchers, suppliers, and its internal personnel, including user and compliance management. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data, administrative, compliance and reporting.

  • Revenue in USD (TTM)10.51m
  • Net income in USD-10.20m
  • Incorporated2009
  • Employees53.00
  • Location
    iSpecimen Inc450 Bedford St Ste 1010LEXINGTON 02420-1535United StatesUSA
  • Phone+1 (781) 301-6700
  • Fax+1 (302) 655-5049
  • Websitehttp://www.ispecimen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Raadr Inc0.00-2.74m3.87m1.00---------18,955.22-18,955.220.00-3,536.270.00----0.00-172,517.00-----------------0.7905--------35.23------
Leafly Holdings Inc38.10m-6.33m3.91m130.00------0.1026-2.95-2.9517.65-5.951.70--13.16293,061.50-28.27---446.03--89.10---16.61-----1.371.96---10.79---287.34------
springbig Holdings Inc26.77m-6.17m3.97m83.00------0.1483-0.1466-0.14660.5118-0.18363.39--6.87322,469.90-78.22------72.60---23.06-----1.59----5.34--21.74------
Rubicon Technologies Inc668.13m-86.01m3.97m340.00------0.006-1.98-1.0214.47-1.493.51--5.841,965,088.00-48.65------6.13---13.86-----1.584.83--3.29---88.85------
Versus Systems Inc110.61k-9.88m4.26m14.00--0.4399--38.51-6.69-6.690.06713.800.0196--6.99---174.80-166.70-84.12-113.0411.90---8,928.70-1,608.99----0.00---75.54193.2753.22---57.63--
iSpecimen Inc10.51m-10.20m4.31m53.00--0.4817--0.4105-21.50-21.5021.779.300.713--3.89198,236.00-69.19-49.18-98.03-145.1650.0853.26-97.04-90.30----0.00---4.5617.70-8.33--35.84--
OLB Group Inc22.62m-25.15m4.31m26.00--0.5214--0.1907-15.91-15.9113.644.600.8403--22.66870,091.10-93.29-31.01-125.41-35.0127.3327.80-111.03-40.08----0.0359--0.667327.65-184.58------
Vynleads Inc0.00-261.69k4.34m1.00---------0.0226-0.02260.00-0.07270.00----0.00-1,423.00-489.67------25.24---334.77---8.05-----100.00--3.72------
Signing Day Sports Inc576.34k-7.53m4.35m14.00------7.54-0.5831-0.58310.0451-0.05720.2348--21.7241,167.14-306.83------74.75---1,306.99-----14.321.49--292.62--17.92------
Infobird Co Ltd280.00k-21.15m4.49m11.00--0.0527--16.04-44.63-162.900.711442.880.0063--3.1125,454.54-48.56-12.84-66.79-24.6055.2661.19-7,656.71-46.71---4.290.00-----56.88-1,208.43------
Motorsport Games Inc8.35m1.31m4.74m46.002.460.97062.480.56730.49580.49583.081.260.8131--8.99167,037.60-4.47-81.17-8.46-207.0564.7556.34-5.50-144.45---17.520.0098---33.08-14.0863.74--101.29--
XY Labs Inc15.74m-1.65m4.79m22.00------0.3041-0.0374-0.03740.3557-0.03752.911.1921.19715,340.00-30.59------95.43---10.51--0.5577------73.03--200.37------
Data as of Nov 13 2024. Currency figures normalised to iSpecimen Inc's reporting currency: US Dollar USD

Institutional shareholders

3.88%Per cent of shares held by top holders
HolderShares% Held
FNY Capital Management LPas of 30 Sep 202411.50k1.76%
BlackRock Fund Advisorsas of 30 Jun 20242.83k0.43%
HRT Financial LP (US)as of 30 Jun 20242.30k0.35%
Virtu Americas LLCas of 30 Jun 20242.10k0.32%
Geode Capital Management LLCas of 30 Jun 20241.93k0.29%
The Vanguard Group, Inc.as of 30 Jun 20241.80k0.28%
Citadel Securities LLCas of 30 Jun 20241.28k0.20%
Jane Street Capital LLCas of 30 Jun 2024994.000.15%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024690.000.11%
Bank of America, NA (Private Banking)as of 30 Jun 20242.000.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.